885619-01-2

Upstream product

• 62-53-3 aniline 
• 52579-16-5 ethyl N-(ethoxycarbonylcyanomethyl) formimidate 
• 122-51-0 orthoformic acid triethyl ester 
• 32683-02-6 ethyl-2-aminocyano acetate 
• 6780-49-0 ethyl N-phenylformimidate 
• 78-39-7 Triethyl orthoacetate 
• 105-56-6 ethyl 2-cyanoacetate 
• 64-17-5 ethanol 
• 155579-42-3 5-amino-1-phenyl-1H-imidazole-4-carbonitrile 

Downstream Products

• 6334-42-5 1,9-dihydro-9-phenyl-6H-purin-6-one 
• 885618-26-8 2-(4-bromo-phenyl)-1-(4-chloro-phenyl)-9-phenyl-1,9-dihydro-purin-6-one 
• 1019996-17-8 C₂₄H₁₇BrN₄O₂ 
• 1132702-97-6 C₃₀H₂₆N₃O₂P 
• 885614-45-9 1-(4-bromo-phenyl)-2-(4-methyl-phenyl)-9-phenyl-1,9-dihydro-purin-6-one 
• 5470-24-6 6-Chloro-9-phenyl-9H-purine 

Relevant academic research and scientific papers

Three-component condensation of 5-aminoimidazole derivatives with aldehydes and Meldrum's acid. Synthesis of 3,4,6,7-tetrahydroimidazo[4,5-b]pyridin-5-ones

A convenient method for the synthesis of the earlier unknown substituted 3,4,6,7-tetrahydroimidazo[4,5-b]pyridin-5-ones was developed based on a three-component condensation of 5-aminoimidazole derivatives, aldehydes, and Meldrum's acid. Unstable aminoimidazole derivatives were readily formed in situ by decarboxylation of 5-amino-4-imidazolecarboxylic acids in acidic medium at room temperature, whose sodium salts were obtained by the alkaline hydrolysis of the corresponding, readily available esters.

A tricyclic derivative of imidazoli [4,5-d]pyrimidone and antitumor use

The present invention relates to an imidazole [4,5-d] tricyclic derivative of pyrimidone and an antitumor use. The compound takes ethyl cyanoacetate as the initial raw material, reacts with sodium nitrite in aqueous acetic acid solution to give ethyl cyanohydroxyiminoacetate, and then reduces sodium disulfite in saturated sodium bicarbonate to give 2-amino-2-cyanoacetic acid ethyl ester, and then reacts with appropriate amines and triethyl orthoformate to give 3 differently substituted 4-aminoimidazolium-5-carboxylate ethyl ester, and finally under the catalysis of trichlorooxyphos, respectively, with δ - valerolactam and ε - caprolactam reaction to obtain a condensed imidazole [4,5- d] Tricyclic derivatives of pyrimidone (d1-d18 and e1-e13) and investigated the inhibitory effects of 31 compounds on HT-29 human colon cancer cells, MCF-7 breast cancer cells and HeLa human cervical cancer cells, respectively. The results showed that with doxycycline as the positive control drug, the activity screening results showed that 5 compounds had certain inhibitory activity on HT-29 human colon cancer cells, 4 compounds had certain inhibitory activity on MCF-7 human breast cancer cells, and 17 compounds had certain inhibitory activity on HeLa human cervical cancer cells.

Efficient synthesis and biological evaluation of 1,2,9-trisubstituted 1,9-dihydro-6H-purin-6-ones

The carbodiimides 4, obtained from aza-Wittig reactions of iminophosphorane 3 with aromatic isocyanates, reacted with amines in the presence of a catalytic amount of RO-Na+ to give the 1,2,9-trisubstituted 1,9-dihydro-6H-purin-6-ones

FUSED PYRIMIDINONE COMPOUNDS AS MGLUR LIGANDS

The invention relates to compounds of Formula (I) wherein the substituents are as defined in claim 1; to compositions comprising said compounds and to their use as pharmaceutical agents.

COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).